American Journal of Ophthalmology
Volume 142, Issue 1 , Pages 10-16.e1 , July 2006

Photodynamic Therapy With Verteporfin and Intravitreal Triamcinolone Acetonide in the Treatment of Neovascular Age-related Macular Degeneration

  • Erdem Ergun, MD

      Affiliations

    • Department of Ophthalmology, Sanatorium Hera, Vienna, Austria
    • Corresponding Author InformationInquiries to Erdem Ergun, MD, Department of Ophthalmology, Sanatorium Hera, Loeblichgasse 14, A-1090 Vienna, Austria
    • ,
  • Noémi Maár, MD

      Affiliations

    • Department of Ophthalmology, Medical University Vienna, Vienna, Austria
    • ,
  • Siamak Ansari-Shahrezaei, MD

      Affiliations

    • Department of Ophthalmology, Medical University Vienna, Vienna, Austria
    • ,
  • Barbara Wimpissinger, MD

      Affiliations

    • Department of Ophthalmology, Rudolf Foundation, Vienna, Austria
    • ,
  • Katharina Krepler, MD

      Affiliations

    • Department of Ophthalmology, Rudolf Foundation, Vienna, Austria
    • ,
  • Andreas Wedrich, MD

      Affiliations

    • Department of Ophthalmology, Medical University Graz, Graz, Austria
    • ,
  • Michael Stur, MD

      Affiliations

    • Department of Ophthalmology, Medical University Vienna, Vienna, Austria

,Accepted 21 February 2006.

References 

  1. Zawinka C , Ergun E , Stur M . Prevalence of patients presenting with neovascular age-related macular degeneration in an urban population . Retina . 2005;25:324–331
  2. Ergun E , Abramov A , Zawinka C , Stur M . Incidence of patients presenting with exudative maculopathy and neovascular disease in an urban population . Wien Klin Wochenschr . 2004;116:737–743
  3. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of two randomized clinical trials. TAP report 1 . Arch Ophthalmol . 1999;117:1329–1345
  4. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. TAP report no. 2 . Arch Ophthalmol . 2001;119:198–207
  5. Blumenkranz MS , Bressler NM , Bressler SB , Donati G , Fish GE  Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group . Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of two randomized clinical trials. TAP report 5 . Arch Ophthalmol . 2002;120:1307–1314
  6. Verteporfin in Photodynamic Therapy (VIP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. VIP report no. 2 . Am J Ophthalmol . 2001;131:541–560
  7. Verteporfin in Photodynamic Therapy (VIP) Study Group . Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia: with verteporfin: One-year results of a randomized clinical trial. VIP report no. 1 . Ophthalmology . 2001;108:841–852
  8. Rubin GS , Bressler NM  Treatment of Age-related Macular Degeneration with Photodynamic Therapy (TAP) Study Group . Effects of verteporfin therapy on contrast on sensitivity: results from the Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) investigation. TAP report . Retina . 2002;22:536–544
  9. Schmidt-Erfurth U , Hasan T . Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration . Surv Ophthalmol . 2000;45:195–214
  10. Sharma S , Brown GC , Brown MM , et al.   The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration . Ophthalmology . 2001;108:2051–2059
  11. Wormald R , Evans J , Smeeth L , Henshaw K . Photodynamic therapy for neovascular age-related macular degeneration . Cochrane Database Syst Rev . 2005;4: CD002030
  12. Michels S , Schmidt-Erfurth U . Sequence of early vascular events after photodynamic therapy . Invest Ophthalmol Vis Sci . 2003;44:2147–2154
  13. Kvanta A , Alggvere PV , Berglin L , Seregard S . Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor . Invest Ophthalmol Vis Sci . 1996;37:1929–1934
  14. Bok D . Evidence for an inflammatory process in age-related macular degeneration gains new support . Proc Natl Acad Sci USA . 2005;102:7053–7054
  15. Oh H , Takagi H , Tagaki T , et al.   The potential angiogenic role of macrophages in the formation of choroidal neovascularization . Invest Ophthalmol Vis Sci . 1999;40:1891–1898
  16. Killingsworth MC , Sarks JP , Sarks SH . Macrophages related to Bruch’s membrane in age-related macular degeneration . Eye . 1990;4:613–621
  17. Dastgheib K , Green WR . Granulomatous reaction to Bruch’s membrane in age-related macular degeneration . Arch Ophthalmol . 1994;112:813–818
  18. Danis RP , Bingaman DP , Yang Y , Ladd L . Inhibition of preretinal and optic nerve head neovascularization in pigs by intravitreal triamcinolone acetonide . Ophthalmology . 1996;103:2099–2104
  19. Smithen LM , Ober MD , Maranan L , Spaide RF . Intravitreal triamcinolone acetonide and intraocular pressure . Am J Ophthalmol . 2004;138:740–743
  20. Penfold P , Gyory J , Hunyor A , Billson F . Exudative macular degeneration and intravitreal triamcinolone (a pilot study) . Aust NZ J Ophthalmol . 1995;23:293–298
  21. Challa JK , Gillies MC , Penfold PL , et al.   Exudative macular degeneration and intravitreal triamcinolone (18 month follow-up) . Aust NZ J Ophthalmol . 1998;26:277–281
  22. Danis RP , Ciulla TA , Pratt LM , Anliker W . Intravitreal triamcinolone in exudative age-related macular degeneration . Retina . 2000;20:244–250
  23. Jonas JB , Kreissig I , Degenring RF . Factors influencing visual acuity after intravitreal triamcinolone acetonide as treatment of exudative age-related macular degeneration . Br J Ophthalmol . 2004;88:1557–1562
  24. Spaide RF , Sorenson J , Maranan L . Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization . Ophthalmology . 2005;112:301–304
  25. Spaide RF , Sorenson J , Maranan L . Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization . Ophthalmology . 2003;110:1517–1525
  26. Rechtman E , Danis RP , Pratt LM , Harris A . Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age-related macular degeneration . Br J Ophthalmol . 2004;88:344–347
  27. Verteporfin Roundtable Participants . Guidelines for using verteporfin (visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes (update) . Retina . 2005;25:119–134
  28. Visudyne in Minimally Classic Choroidal Neovascularization Study Group . Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration (Two-year results of a randomized clinical trial) . Arch Ophthalmol . 2005;123:448–457
  29. Macular Photocoagulation Study Group . Argon laser photocoagulation for neovascular maculopathy (five-year results from randomized clinical trials) . Arch Ophthalmol . 1991;109:1109–1114
  30. Macular Photocoagulation Study Group . Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration (updated findings from two clinical trials) . Arch Ophthalmol . 1993;111:1200–1209
  31. Macular Photocoagulation Study Group . Krypton laser photocoagulation for neovascular lesions of age-related macular degeneration (results of a randomized clinical trial) . Arch Ophthalmol . 1996;114:400–412
  32. Macular Photocoagulation Study Group . Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration (results of a randomized clinical trial) . Arch Ophthalmol . 1991;109:1220–1231
  33. Macular Photocoagulation Study Group . Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy . Arch Ophthalmol . 1986;104:503–512
  34. Macular Photocoagulation Study Group . Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration (the influence of initial lesion size and initial visual acuity) . Arch Ophthalmol . 1994;112:480–488
  35. Boscia F , Furino C , Prascina F , Delle Noci N , Sborgia L , Sborgia C . Combined surgical ablation and intravitreal triamcinolone acetonide for retinal angiomatous proliferation . Eur J Ophthalmol . 2005;15:513–516
  36. Smithen LM , Ober MD , Maranan L , Spaide RF . Intravitreal triamcinolone acetonide and intraocular pressure . Am J Ophthalmol . 2004;138:740–743

 Supported in part by an unrestricted Scientific Financial Grant by Novartis AG (Basel, Switzerland).

PII: S0002-9394(06)00343-6

doi: 10.1016/j.ajo.2006.02.048

American Journal of Ophthalmology
Volume 142, Issue 1 , Pages 10-16.e1 , July 2006

Article Tools

* Image Usage & Resolution